Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
[Paper-level Aggregated] PMCID: PMC7612475
Evidence Type(s): Oncogenic, Functional, Predictive
Justification: Oncogenic: The SF3B1K700E mutation is associated with a BRCA-like cellular phenotype that compromises homologous recombination (HR) and increases sensitivity to DNA damaging agents, indicating its role in cancer development. Functional: The SF3B1K700E mutation affects the ability of cells to resolve recombination intermediates and induces unscheduled R-loops, leading to stalled replication forks and reduced replication fork protection, demonstrating a functional impact on DNA repair mechanisms. Predictive: The presence of the SF3B1K700E mutation predicts increased sensitivity to PARP inhibitors and other chemotherapeutic agents, suggesting its potential as a therapeutic target in cancer treatment.
Gene→Variant (gene-first): RNASEH1(246243):D210N SF3B1(23451):K700E
Genes: RNASEH1(246243) SF3B1(23451)
Variants: D210N K700E